Adagio Completes 13 Ventricular Ablation Procedures Using ULTA Technology
- Technological Breakthrough: Adagio Medical has successfully completed 13 ventricular ablation procedures using its proprietary Ultra-Low Temperature Ablation (ULTA) technology at leading institutions, marking a significant advancement in treating patients with no satisfactory treatment options, showcasing the technology's potential in managing refractory arrhythmias.
- Patient Benefits: These procedures targeted patients who had previously failed conventional and experimental ablation therapies, indicating the effectiveness of ULTA technology in handling complex cases, which may provide new treatment options for cardiac patients and enhance the company's competitiveness in the cardiac ablation market.
- Clinical Need: Under the FDA's Expanded Access authorization, ULTA technology offers treatment opportunities for patients facing serious or life-threatening diseases, emphasizing its importance in managing ventricular arrhythmias and potentially transforming existing treatment paradigms.
- Future Outlook: Adagio plans to apply for FDA approval of its vCLAS™ Cryoablation System by the end of 2026, which is expected to provide broader industry indications for the treatment of ventricular arrhythmias, further solidifying its market position.
Trade with 70% Backtested Accuracy
Analyst Views on ADGM
About ADGM
About the author
Adagio Medical Q4 Earnings Beat Expectations
- Earnings Performance: Adagio Medical Holdings reported a Q4 GAAP EPS of -$0.21, beating market expectations by $0.10, indicating an improving trend in financial performance.
- Significant Cost Reduction: The cost of revenue for Q4 2025 was $58,000, a substantial decrease from $1.5 million in Q4 2024, demonstrating the company's effective cost control measures.
- R&D Spending Decrease: Research and development expenses for Q4 2025 were $2.2 million, down from $3.4 million in Q4 2024, reflecting optimization in resource allocation that may impact future innovation capabilities.
- Net Loss Reduction: The net loss for Q4 2025 was $3.3 million, significantly reduced from $57.4 million in Q4 2024, showcasing positive progress in the company's financial health.
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Content: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing, allowing investors to access content 24/7 for 90 days, thereby increasing attention on small-cap growth companies.
- Investor Participation: The conference invites individual and institutional investors, advisors, and analysts to participate, providing an interactive platform that facilitates direct communication between investors and companies, enhancing investor relations management.
- One-on-One Meeting Opportunities: Selected companies are accepting one-on-one management meeting requests until February 10, offering investors a chance to engage directly with company executives, which deepens investor engagement and trust.
- Advantages of Virtual Conferences: Virtual Investor Conferences replicate the components of on-site investor meetings through real-time investor engagement solutions, enhancing the efficiency of connections between companies and investors and modernizing investor communications.
Deborah Kaster, Chief Business Officer of Adagio Medical, Takes On Additional Role as CFO
Leadership Change at Adagio Medical: Deborah Kaster has been appointed as Chief Financial Officer in addition to her role as Chief Business Officer, effective September 5, 2025, succeeding Dan George.
Kaster's Background: Kaster joined Adagio Medical in March 2025 and has extensive experience in investor relations and business development, having previously worked at Shockwave Medical, Gilmartin Group, and Kyphon.
3 Penny Stocks to Watch Now, 4/22/25
Penny Stocks to Watch: Adagio Medical, China SXT Pharmaceuticals, and Motorsport Games are highlighted as penny stocks to monitor on April 22, 2025, based on their high Dollar Volume despite recent stock price declines.
Company Highlights: Adagio Medical focuses on cardiac arrhythmia treatments and received FDA recognition; China SXT Pharmaceuticals faced a significant drop amid market issues; Motorsport Games regained Nasdaq compliance but also saw a stock price decrease.
Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System
Breakthrough Device Designation: Adagio Medical has received FDA Breakthrough Device designation for its vCLAS™ Cryoablation System, aimed at treating drug-refractory ventricular tachycardia (VT), which allows for priority review and faster access to the device for patients.
Clinical Study and Technology: The vCLAS™ system utilizes proprietary Ultra-Low Temperature Cryoablation technology and is currently being evaluated in a clinical study (FULCRUM-VT) to support its application for FDA premarket approval, with the goal of improving treatment outcomes for patients with VT.
Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director
Leadership Change at Adagio Medical: Olav Bergheim has stepped down as CEO and Chairperson of Adagio Medical Holdings, effective December 13, 2024, with Todd Usen appointed as the new CEO and Orly Mishan as Chairperson. Bergheim will remain as an advisor during the transition period.
Future Plans for Adagio: Todd Usen expressed enthusiasm about leading Adagio through its commercial efforts in Europe and the FULCRUM-VT trial in the U.S., highlighting the potential of Adagio's VT Cryoablation System to become a standard treatment for ventricular tachycardia.
Adagio Medical Q4 Earnings Beat Expectations
- Earnings Performance: Adagio Medical Holdings reported a Q4 GAAP EPS of -$0.21, beating market expectations by $0.10, indicating an improving trend in financial performance.
- Significant Cost Reduction: The cost of revenue for Q4 2025 was $58,000, a substantial decrease from $1.5 million in Q4 2024, demonstrating the company's effective cost control measures.
- R&D Spending Decrease: Research and development expenses for Q4 2025 were $2.2 million, down from $3.4 million in Q4 2024, reflecting optimization in resource allocation that may impact future innovation capabilities.
- Net Loss Reduction: The net loss for Q4 2025 was $3.3 million, significantly reduced from $57.4 million in Q4 2024, showcasing positive progress in the company's financial health.
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Content: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing, allowing investors to access content 24/7 for 90 days, thereby increasing attention on small-cap growth companies.
- Investor Participation: The conference invites individual and institutional investors, advisors, and analysts to participate, providing an interactive platform that facilitates direct communication between investors and companies, enhancing investor relations management.
- One-on-One Meeting Opportunities: Selected companies are accepting one-on-one management meeting requests until February 10, offering investors a chance to engage directly with company executives, which deepens investor engagement and trust.
- Advantages of Virtual Conferences: Virtual Investor Conferences replicate the components of on-site investor meetings through real-time investor engagement solutions, enhancing the efficiency of connections between companies and investors and modernizing investor communications.
Deborah Kaster, Chief Business Officer of Adagio Medical, Takes On Additional Role as CFO
Leadership Change at Adagio Medical: Deborah Kaster has been appointed as Chief Financial Officer in addition to her role as Chief Business Officer, effective September 5, 2025, succeeding Dan George.
Kaster's Background: Kaster joined Adagio Medical in March 2025 and has extensive experience in investor relations and business development, having previously worked at Shockwave Medical, Gilmartin Group, and Kyphon.
3 Penny Stocks to Watch Now, 4/22/25
Penny Stocks to Watch: Adagio Medical, China SXT Pharmaceuticals, and Motorsport Games are highlighted as penny stocks to monitor on April 22, 2025, based on their high Dollar Volume despite recent stock price declines.
Company Highlights: Adagio Medical focuses on cardiac arrhythmia treatments and received FDA recognition; China SXT Pharmaceuticals faced a significant drop amid market issues; Motorsport Games regained Nasdaq compliance but also saw a stock price decrease.
Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System
Breakthrough Device Designation: Adagio Medical has received FDA Breakthrough Device designation for its vCLAS™ Cryoablation System, aimed at treating drug-refractory ventricular tachycardia (VT), which allows for priority review and faster access to the device for patients.
Clinical Study and Technology: The vCLAS™ system utilizes proprietary Ultra-Low Temperature Cryoablation technology and is currently being evaluated in a clinical study (FULCRUM-VT) to support its application for FDA premarket approval, with the goal of improving treatment outcomes for patients with VT.
Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director
Leadership Change at Adagio Medical: Olav Bergheim has stepped down as CEO and Chairperson of Adagio Medical Holdings, effective December 13, 2024, with Todd Usen appointed as the new CEO and Orly Mishan as Chairperson. Bergheim will remain as an advisor during the transition period.
Future Plans for Adagio: Todd Usen expressed enthusiasm about leading Adagio through its commercial efforts in Europe and the FULCRUM-VT trial in the U.S., highlighting the potential of Adagio's VT Cryoablation System to become a standard treatment for ventricular tachycardia.
